Skip to main content
. 2020 Apr 20;8(1):e000410. doi: 10.1136/jitc-2019-000410

Figure 5.

Figure 5

Coexpression of HLA class I and NY-ESO-1. Percentage change (top panels) in the number of double-positive Human Leukocyte Antigen (HLA)+/NY-ESO-1+ cells relative to prevaccination, and evidence of pre-existing (P) or vaccine-induced (V) anti-NY-ESO-1 immunity in a representative number of participants who received (A) NY-ESO-1/ISCOMATRIX or (B) ISCOMATRIX alone. Red: positive response for three of three markers (ie, CD4+, CD8+, Ab+). Yellow: positive response for two of three markers. Green: positive response for one of three markers. Blue: negative response for all three markers. Gray: data not available for this patient. Bottom panels: representative multiplex immunofluorescence for HLA class I (red) and NY-ESO-1 (green) prevaccination and post-vaccination in a patient (075–015) who received NY-ESO-1/ISCOMATRIX, and in a patient (075–009) who received ISCOMATRIX alone. DP, Double positive HLA class I+/ NY-ESO-1+ cells. M, single HLA class I+ cells. NY, single NY-ESO-1+ cells. Cell nuclei are stained with 4′,6-diamidino-2-phenylindole (DAPI), magnification: ×20.